The candidate Lyme disease vaccine, VLA15, in clinical development by the European biotech, Valneva SE, has just reported positive initial results in the first of two Phase II studies and, with further results expected in coming months from the Phase II program, Valneva says it is “working with Pfizer Inc. to advance the development of VLA15 expeditiously.”
Valneva and Pfizer entered into an agreement at the end of April this year to develop VLA15, in which Valneva received a $130m upfront payment and is line for milestones and royalties in the future if the vaccine is successfully developed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?